These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 16231592

  • 1. Steatosis and hepatocellular carcinoma risk.
    Smedile A, Bugianesi E.
    Eur Rev Med Pharmacol Sci; 2005; 9(5):291-3. PubMed ID: 16231592
    [Abstract] [Full Text] [Related]

  • 2. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A, Orive A, García-Suárez C, Domínguez A, Fernández-Escalante JC, Crespo J, Pons-Romero F.
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [Abstract] [Full Text] [Related]

  • 3. Hepatocellular carcinoma with nonalcoholic steatohepatitis.
    Mori S, Yamasaki T, Sakaida I, Takami T, Sakaguchi E, Kimura T, Kurokawa F, Maeyama S, Okita K.
    J Gastroenterol; 2004 Mar; 39(4):391-6. PubMed ID: 15168253
    [Abstract] [Full Text] [Related]

  • 4. Obesity and diabetes as a risk factor for hepatocellular carcinoma.
    Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J.
    Liver Transpl; 2004 Feb; 10(2 Suppl 1):S69-73. PubMed ID: 14762843
    [Abstract] [Full Text] [Related]

  • 5. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder.
    Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F.
    Pathol Int; 2006 Jan; 56(1):40-5. PubMed ID: 16398679
    [Abstract] [Full Text] [Related]

  • 6. Review article: steatosis, the metabolic syndrome and cancer.
    Bugianesi E.
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():40-3. PubMed ID: 16225471
    [Abstract] [Full Text] [Related]

  • 7. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
    Pekow JR, Bhan AK, Zheng H, Chung RT.
    Cancer; 2007 Jun 15; 109(12):2490-6. PubMed ID: 17487861
    [Abstract] [Full Text] [Related]

  • 8. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
    Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS.
    Hepatology; 2002 Dec 15; 36(6):1349-54. PubMed ID: 12447858
    [Abstract] [Full Text] [Related]

  • 9. Chronic liver disease in diabetes mellitus.
    Amarapurkar D, Das HS.
    Trop Gastroenterol; 2002 Dec 15; 23(1):3-5. PubMed ID: 12170918
    [Abstract] [Full Text] [Related]

  • 10. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar 15; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [Abstract] [Full Text] [Related]

  • 11. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.
    Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K, Shiratori K.
    J Gastroenterol; 2004 Dec 15; 39(12):1215-8. PubMed ID: 15622489
    [Abstract] [Full Text] [Related]

  • 12. NASH and HCC.
    Page JM, Harrison SA.
    Clin Liver Dis; 2009 Nov 15; 13(4):631-47. PubMed ID: 19818310
    [Abstract] [Full Text] [Related]

  • 13. Nonalcoholic steatohepatitis.
    Brunt EM.
    Semin Liver Dis; 2004 Feb 15; 24(1):3-20. PubMed ID: 15085483
    [Abstract] [Full Text] [Related]

  • 14. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Malik SM, Gupte PA, de Vera ME, Ahmad J.
    Clin Gastroenterol Hepatol; 2009 Jul 15; 7(7):800-6. PubMed ID: 19281869
    [Abstract] [Full Text] [Related]

  • 15. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.
    Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R.
    J Hepatol; 2009 Feb 15; 50(2):351-7. PubMed ID: 19070395
    [Abstract] [Full Text] [Related]

  • 16. Primary liver cancers with nonalcoholic steatohepatitis.
    Hashizume H, Sato K, Takagi H, Hirokawa T, Kojima A, Sohara N, Kakizaki S, Mochida Y, Shimura T, Sunose Y, Ohwada S, Mori M.
    Eur J Gastroenterol Hepatol; 2007 Oct 15; 19(10):827-34. PubMed ID: 17873605
    [Abstract] [Full Text] [Related]

  • 17. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.
    Liver Int; 2011 Mar 15; 31(3):377-85. PubMed ID: 21108736
    [Abstract] [Full Text] [Related]

  • 18. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis.
    Miele L, Forgione A, Hernandez AP, Gabrieli ML, Vero V, Di Rocco P, Greco AV, Gasbarrini G, Gasbarrini A, Grieco A.
    Eur Rev Med Pharmacol Sci; 2005 Mar 15; 9(5):273-7. PubMed ID: 16231589
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
    N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, Trinchet JC, Beaugrand M.
    Clin Gastroenterol Hepatol; 2006 Aug 15; 4(8):1062-8. PubMed ID: 16844421
    [Abstract] [Full Text] [Related]

  • 20. Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients.
    Jain D, Nayak NC, Saigal S.
    Eur J Gastroenterol Hepatol; 2012 Jul 15; 24(7):840-8. PubMed ID: 22495397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.